|
US2017112902A1
|
|
Methods of treating amyotrophic lateral sclerosis by HGF
|
|
JP2011050626A
|
|
Neck manipulative instrument
|
|
US2006030517A1
|
|
Anti-cancer agent
|
|
EP1695982A1
|
|
Glycosylation-deficient hepatocyte growth factor
|
|
CN1894280A
|
|
Glycosylation-deficient hepatocyte growth factor
|
|
US2006199762A1
|
|
Skin ulcer preventive curative agent containing human recombinant hgf
|
|
AU2004200074A1
|
|
Agent for relieving side effects caused by immunosuppressants
|
|
EP1103269A1
|
|
Use of HGF for the treatment of ischemic diseases of the extremities
|
|
WO9955361A1
|
|
Neovascularization inhibitors
|
|
EP1036566A1
|
|
Preparation for continuous intravenous administration
|
|
EP0979097A1
|
|
Hgf for treating acute renal failure
|
|
CA2218145A1
|
|
Method of treating dilated cardiomyopathy
|
|
EP0816381A1
|
|
Polyethylene glycol modified hepatocyte growth factor (hgf)
|
|
WO9404175A1
|
|
Hgf production promoter
|
|
EP0859009A2
|
|
Recombinant human hepatocyte growth factor and method for production thereof
|
